ASUS has achieved a significant milestone in its smart healthcare journey with the certification of its VivoWatch blood pressure application by Thailand’s Food and Drug Administration (FDA Thai). Announced on 9 December, the app, bearing Thailand FDA number 67-2-2-2-0009328, becomes the first overseas medical software developed by ASUS to receive such certification. This accomplishment highlights ASUS’ commitment to advancing healthcare technology in Southeast Asia.
Joe Hsieh, Chief Operating Officer and Global Senior Vice President of ASUS, expressed enthusiasm about the development. “We are excited to bring our innovative health management solutions to the Thai market,” he said. “This certification from the Food and Drug Administration of Thailand is a testament to our dedication in creating reliable and effective health technology that empowers users to take control of their health.”
Cutting-edge technology for blood pressure monitoring
The ASUS VivoWatch blood pressure application, independently developed by the company, is already certified by the Taiwan Food and Drug Administration. The app integrates with supported ASUS VivoWatch devices, offering users a comprehensive health management tool. It allows users to monitor, record, and display essential metrics such as systolic and diastolic blood pressure readings and heart rate.
By the end of the year, the app will support various ASUS VivoWatch models, including VivoWatch 6, VivoWatch 5, VivoWatch 5 AERO, and VivoWatch SP, in Thailand. With these capabilities, ASUS aims to empower users with real-time health insights, helping them make informed decisions about their well-being.
Partnerships driving innovation in healthcare
ASUS is collaborating with leading healthcare providers and elderly care centres in Thailand to introduce innovative healthcare models. The VivoWatch devices will play a crucial role in collecting long-term health data from elderly users. This data will be used to create personalised health management plans and promote remote healthcare services, addressing the specific needs of Thailand’s ageing population.
Additionally, ASUS has built successful partnerships with prominent hospitals in Taiwan, leveraging mobile health (mHealth) technology and continuous physiological monitoring. These collaborations have positioned ASUS as a key player in digital healthcare, bridging technology and personalised medical care.
The Thailand FDA certification marks a pivotal step in ASUS’ broader healthcare strategy, showcasing its ability to meet stringent medical standards while offering practical, user-focused solutions. With this achievement, ASUS continues to reinforce its presence in the Southeast Asian healthcare market, setting the stage for future innovations in health technology.
